Separately, the brand's site references published clinical-trial data for the drug class itself, stating that "tirzepatide and semaglutide have shown 15-20% body weight reduction in clinical trials." That figure describes the medication class in general clinical research - not Telos Rx's specific patient outcomes, and the two data points shouldn't be conflated
This improvement is typically linked to better blood glucose control, weight loss, and overall metabolic health rather than a direct pharmacological effect on energy
However, we did not find a dose-dependent change in average drinks or AUDIT scores in the medication groups, although a visual downward trend could be observed in the Tirzepatide group
That sounds excellent for weight loss and it is
Or read about three women who say side effects made them question whether GLP-1s were worth it
Clinical criteria for approval of a BBG drug that requires PA are all of these: Note: Member or prescriber preference for the use of a BBG drug will not be considered as criteria to support the need for a BBG drug